# Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab

> **NCT03457818** · PHASE2 · TERMINATED · sponsor: **Mishaela Rubin** · enrollment: 8 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Osteoporosis

## Interventions

- **DRUG:** Denosumab 60 mg/ml [Prolia]
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03457818
- **Lead sponsor:** Mishaela Rubin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-07
- **Primary completion:** 2020-06-10
- **Final completion:** 2020-06-10
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Due to enrollment difficulties compounded by the COVID pandemic.
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03457818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03457818, "Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03457818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*